Bio-Rad Laboratories, Inc.

Report azionario NYSE:BIO

Capitalizzazione di mercato: US$7.1b

Bio-Rad Laboratories Gestione

Criteri Gestione verificati 4/4

Bio-Rad Laboratories Il CEO è Norman Schwartz, nominato in Jan2003, e ha un mandato di 23.33 anni. la retribuzione annua totale è $ 8.00M, composta da 13.6% di stipendio e 86.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 6.3% delle azioni della società, per un valore di $ 448.24M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.2 anni e 9.1 anni.

Informazioni chiave

Norman Schwartz

Amministratore delegato

US$8.0m

Compenso totale

Percentuale dello stipendio del CEO13.63%
Mandato del CEO23.3yrs
Proprietà del CEO6.3%
Durata media del management2.2yrs
Durata media del Consiglio di amministrazione9.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

BIO: Completed Buybacks And Intangible Impairment Will Support Future Upside

Analysts maintained their $320.00 price target for Bio-Rad Laboratories, making only minor adjustments to assumptions for discount rate, revenue, profit margin, and future P/E ratio to support this unchanged outlook. What's in the News Reported impairment charges of purchased intangibles and related items of $172.8 million for the fourth quarter ended December 31, 2025 (Key Developments).

BIO: Buybacks And Intangible Impairment Will Shape Balanced Forward Expectations

Analysts have reset their price target on Bio-Rad Laboratories from $375 to $320, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43 million under the buyback program announced on July 20, 2023 (Key Developments).

BIO: Share Repurchase And Higher Margin Outlook Will Support Future Upside

Analysts have reduced their price target on Bio-Rad Laboratories from $348.00 to $321.25, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that result in a slightly more conservative valuation framework. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback that was announced on July 20, 2023 (Key Developments).

BIO: Share Repurchases And Intangible Impairment Will Shape Future Upside

Analysts have maintained their $375.00 price target for Bio-Rad Laboratories, citing only minor adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated model inputs rather than a change in their overall view. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).

BIO: Share Repurchases And Margin Outlook Will Support Future Upside

Analysts have maintained their price target for Bio-Rad Laboratories at $375, citing updated assumptions that include slightly higher revenue, improved profit margins, and a lower future P/E multiple, which together support the unchanged assessment of fair value. What's in the News From October 1, 2025 to December 31, 2025, Bio-Rad Laboratories reported no additional share repurchases, with 0 shares bought for $0, under its existing buyback program (Key Developments).

BIO: Share Repurchases Will Support Future Upside Despite Impairment Charges

Analysts are keeping their price target for Bio-Rad Laboratories steady at $375, with updated assumptions that include a slightly higher discount rate, a higher revenue growth outlook, a lower profit margin, and a higher future P/E multiple to reflect their latest view of the risk and return profile. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of the company, for a total of US$715.43 million under the buyback announced on July 20, 2023 (Key Developments).

BIO: Fair Outlook Will Balance Richer Margins Against Higher Required Returns

Analysts have lifted their price target on Bio-Rad Laboratories from US$265 to US$325, reflecting updated views on slightly different growth assumptions, a higher projected profit margin, and an adjusted future P/E multiple. Valuation Changes Fair Value: updated from US$265 to US$325, indicating a higher implied valuation level.

Bio-Rad Laboratories Still Hampered By Underwhelming Core Growth

Jan 22

BIO: Share Buybacks And Oncology Assay Partnership Will Drive Future Upside

Analysts have kept their price target for Bio-Rad Laboratories broadly steady at about US$375.00, reflecting only slight adjustments to modeled discount rate, revenue growth, profit margin, and future P/E assumptions in their updated views. What's in the News From July 1, 2025 to September 30, 2025, Bio-Rad repurchased 212,578 shares, about 0.79% of its shares, for US$52.83 million under its existing buyback program.

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jan 06
Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

BIO: Share Buybacks And Oncology Partnership Will Support Future Upside

Analysts have lowered their price target on Bio-Rad Laboratories from US$437 to US$375, based on updated assumptions that combine more moderate revenue growth expectations with a slightly higher discount rate and a lower future P/E, partially offset by a higher projected profit margin. What's in the News Completed share repurchase of 2,614,132 shares, or 9.26% of the company, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).

BIO: Share Repurchase Will Drive Attractive Shareholder Returns Ahead

Narrative Update on Bio-Rad Laboratories Analysts have reaffirmed their conviction in Bio-Rad Laboratories, with the price target effectively unchanged at approximately 348 dollars. Modest tweaks to the discount rate, long-term revenue growth, profit margin, and future valuation assumptions largely offset one another in updated models.

BIO: Share Repurchase and Expanded Partnership Will Shape Performance in Coming Quarters

Analysts have maintained their price target for Bio-Rad Laboratories at $348.00, noting only minor adjustments to revenue growth and profit margin expectations this quarter. What's in the News Bio-Rad Laboratories completed the repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for $715.43 million under a buyback program announced in July 2023.

BIO: Share Repurchase and Expanded Partnerships Will Influence Future Performance

Analysts have raised their price target for Bio-Rad Laboratories from $324 to $348. They cite updated financial assumptions as well as small shifts in projected growth rates and profitability.

BIO: Expanded Diagnostics Partnership Will Drive Margin Improvements Amid Mixed Revenue Outlook

Analysts have raised their price target for Bio-Rad Laboratories from $310 to $324, reflecting updated profit margin estimates. These changes more than offset slightly lower revenue growth expectations.

Molecular Diagnostics Expansion Will Unlock Potential While Cost Challenges Persist

The decline in Bio-Rad Laboratories’ consensus price target to $310.00 primarily reflects lower future P/E and revenue growth expectations. What's in the News Completed buyback of 2,401,554 shares (8.47% of outstanding) for $662.6 million under program announced July 2023.

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Aug 03
Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Jul 14
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
User avatar

Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics

Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.

Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential

Jan 29

Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis

Nov 25

Bio-Rad Laboratories: Overvalued Given Current Growth Prospects

Sep 23

Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar

Jul 14

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Apr 14

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Oct 25

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Norman Schwartz rispetto agli utili di Bio-Rad Laboratories?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

US$169m

Dec 31 2025US$8mUS$1m

US$760m

Sep 30 2025n/an/a

-US$676m

Jun 30 2025n/an/a

US$319m

Mar 31 2025n/an/a

-US$2b

Dec 31 2024US$8mUS$1m

-US$2b

Sep 30 2024n/an/a

-US$779m

Jun 30 2024n/an/a

-US$1b

Mar 31 2024n/an/a

-US$322m

Dec 31 2023US$7mUS$1m

-US$637m

Sep 30 2023n/an/a

-US$159m

Jun 30 2023n/an/a

-US$428m

Mar 31 2023n/an/a

-US$191m

Dec 31 2022US$8mUS$1m

-US$4b

Sep 30 2022n/an/a

-US$6b

Jun 30 2022n/an/a

-US$2b

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$9mUS$988k

US$4b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$4b

Mar 31 2021n/an/a

US$4b

Dec 31 2020US$8mUS$987k

US$4b

Sep 30 2020n/an/a

US$4b

Jun 30 2020n/an/a

US$2b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$7mUS$950k

US$2b

Compensazione vs Mercato: La retribuzione totale di Norman ($USD 8.00M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 8.77M ).

Compensazione vs guadagni: La retribuzione di Norman è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Norman Schwartz (75 yo)

23.3yrs
Mandato
US$7,995,841
Compensazione

Mr. Norman D. Schwartz has been the Chief Executive Officer of Bio-Rad Laboratories, Inc. since January 1, 2003 and has been its Chairman since 2012. Mr. Schwartz was Principal Financial Officer of Bio-Rad...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Norman Schwartz
Chairman & CEO23.3yrsUS$8.00m6.3%
$ 448.2m
Jonathan DiVincenzo
President & COO1.7yrsUS$3.68m0.0034%
$ 241.8k
Roop Lakkaraju
Executive VP & CFO2.1yrsUS$2.99m0.0095%
$ 675.6k
James Barry
Executive VP & President of Life Science Groupno dataUS$2.61m0.0019%
$ 134.4k
Rajat Mehta
Executive Vice President of Global Commercial Operationsless than a yearUS$2.99mNessun dato
Ruben Argueta
Vice President of Investor Relationsno dataNessun datoNessun dato
Matthew Werner
Senior VP and Chief Compliance & Privacy Officerno dataNessun datoNessun dato
Courtney Enloe
Executive VP2.3yrsNessun dato0.0028%
$ 197.7k
Nanditha Yelamanchi
Executive Vice President of Global Human Resourcesno dataNessun datoNessun dato
Michael Crowley
Executive Vice President of Global Commercial Operations11.4yrsUS$2.24m0.030%
$ 2.2m
Erik Molitor
Senior Vice President of Global Technology & Systemsno dataNessun datoNessun dato
Morgan Norris
Senior Vice President of Marketing at Life Science Groupno dataNessun datoNessun dato
2.2yrs
Durata media
54yo
Età media

Gestione esperta: Il team dirigenziale di BIO è considerato esperto (durata media dell'incarico 2.2 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Norman Schwartz
Chairman & CEO31.3yrsUS$8.00m6.3%
$ 448.2m
Gregory Hinckley
Lead Independent Director9.1yrsUS$337.71k0.0045%
$ 320.0k
Jeffrey Edwards
Independent Director9.1yrsUS$324.71k0.0027%
$ 188.4k
Arnold Pinkston
Independent Director9.1yrsUS$309.71k0.0027%
$ 188.4k
Melinda Pei
Independent Director9.1yrsUS$329.71k0.0027%
$ 188.4k
Allison Schwartz
Director4.1yrsNessun dato0.020%
$ 1.4m
9.1yrs
Durata media
66.5yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BIO sono considerati esperti (durata media dell'incarico 9.1 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/05 21:58
Prezzo dell'azione a fine giornata2026/05/05 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Bio-Rad Laboratories, Inc. è coperta da 19 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jon WoodBofA Global Research
Yuan ZhiB. Riley Securities, Inc.
Patrick DonnellyCitigroup Inc